This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
BJ's Wholesale Club (BJ) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BJPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Intercept (ICPT) Earnings and Sales Miss Estimates in Q2
by Zacks Equity Research
Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.
PFENegative Net Change ALKSNegative Net Change ICPTPositive Net Change VKTXNegative Net Change
biotechnology biotechs earnings pharmaceuticals
Ocugen Q2 Preview: Rebound Quarter Inbound?
by Derek Lewis
Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.
OCGNNo Net Change
biotechnology earnings medical
Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.
REGNNegative Net Change SNYPositive Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs earnings pharmaceuticals
U.S. Stock Futures Rise on Strong Q2 Earnings
by Zacks Equity Research
Stock futures have risen in today¿¿¿s pre-market after two consecutive days of loss making.
REGNNegative Net Change ETRNegative Net Change CVSNegative Net Change MRNANegative Net Change
biotechnology retail utilities
Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped
by Zacks Equity Research
Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.
GSKNegative Net Change DVAXNegative Net Change ALKSNegative Net Change GILDPositive Net Change
biotechnology biotechs
NBT Bancorp (NBTB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NBTBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.
GILDPositive Net Change EXELNegative Net Change ZTSNegative Net Change IONSNegative Net Change
biotechnology pharmaceuticals
Clearway Energy (CWEN)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CWENNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bull of the Day: Illumina (ILMN)
by Kevin Cook
Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data
ILMNNegative Net Change NTRANegative Net Change
biotechnology cancer dna-sequencing genetic-testing genomics oncology-screening smart-health
What is in Store for Regeneron (REGN) This Earnings Season?
by Zacks Equity Research
Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.
REGNNegative Net Change SNYPositive Net Change GILDPositive Net Change IONSNegative Net Change
biotechnology earnings
Bavarian Nordic (BVNRY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BVNRYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is a Beat in Store for Gilead (GILD) in This Earnings Season?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) second-quarter 2022 results.
AZNNegative Net Change GILDPositive Net Change RGENNegative Net Change IONSNegative Net Change
biotechnology
Valmont Industries (VMI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
VMIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Stocks With Recent Price Strength to Gain From July Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, FC, ASC, SNEX and ARLP.
ARLPNegative Net Change FCNegative Net Change ASCPositive Net Change SNEXNegative Net Change IMCRNegative Net Change
alt-energy biotechnology business-services finance transportation
Should You Buy Beaten-Down Biotech Stocks & ETFs?
by Neena Mishra
We highlight 4 ETFs that have started rebounding after a brutal sell-off
AMGNNegative Net Change GILDPositive Net Change VRTXNegative Net Change IBBNegative Net Change TDOCPositive Net Change XBINegative Net Change CRSPNegative Net Change ARKGNegative Net Change IBBQNegative Net Change
biotechnology biotechs crispr etfs gene-editing gene-therapy genetic-testing medical
Greif (GEF) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GEFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Covenant Logistics (CVLG)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CVLGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Top Analyst Reports for Johnson & Johnson, Cigna, & Vertex
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Cigna Corporation (CI), and Vertex Pharmaceuticals Incorporated (VRTX).
XELNegative Net Change JNJNegative Net Change CMGNegative Net Change VRTXNegative Net Change ILMNNegative Net Change CINegative Net Change
biotechnology insurance pharmaceuticals
3 Stocks With Momentum Anomaly to Buy on Solid Earnings Rally
by Supriyo Bose
Alkermes plc (ALKS), BancFirst (BANF) and ExlService (EXLS) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
ALKSNegative Net Change BANFPositive Net Change EXLSNegative Net Change
biotechnology business-services computers fin-tech
Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More
by Zacks Equity Research
'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.
INCYNegative Net Change NVAXNegative Net Change APLSNegative Net Change NEXINo Net Change
biotechnology pharmaceuticals
Best Momentum Stocks to Buy for July 20th
by Zacks Equity Research
AN, LAD, and VRNA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 20, 2022.
ANPositive Net Change LADNegative Net Change VRNANegative Net Change
biotechnology medical retail
Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura
by Zacks Equity Research
Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
NVSNegative Net Change ALKSNegative Net Change INCYNegative Net Change SRPTNegative Net Change
biotechnology pharmaceuticals
Enphase Energy (ENPH) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ENPHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
by Zacks Equity Research
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
ALKSNegative Net Change SRPTNegative Net Change SGENPositive Net Change NEXINo Net Change
biotechnology biotechs pharmaceuticals